- Market Realist•6 minutes ago
Among the 26 brokerage companies surveyed by Bloomberg for Biogen (BIIB), 64.0% gave it “buys,” while 36.0% gave it “holds.”
- MarketWatch•9 minutes ago
Shares of Celgene Corp. fell in Monday's extended session after the drug maker decided not the pursue approval for use of Revlimid, a lymphoma drug, in maintenance therapy following a late stage study. ...
After hours: 105.26-2.67 (-2.47%) as of 5:04 PM EDT
|Bid||104.77 x 300|
|Ask||105.05 x 200|
|52wk Range||92.98 - 136.40|
|Day's Range||106.73 - 108.14|
|Avg Vol (3m)||4,365,147|
As of 4:00 PM EDT. Market closed.